TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVA) Net margin 2016–2025
TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVA) net profit margin by fiscal year — reported net income divided by reported revenue.
8.2%FY2025 · since FY2016: 1.5% → 8.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 8.2% | +18.1 pp |
| FY2024 | -9.9% | -6.4 pp |
| FY2023 | -3.5% | +12.9 pp |
| FY2022 | -16.4% | -19.0 pp |
| FY2021 | 2.6% | +26.6 pp |
| FY2020 | -24.0% | -18.0 pp |
| FY2019 | -5.9% | +5.9 pp |
| FY2018 | -11.8% | +62.7 pp |
| FY2017 | -74.4% | -75.9 pp |
| FY2016 | 1.5% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More TEVA financial trends
TEVA RevenueTEVA Net incomeTEVA Gross profitTEVA Gross marginTEVA Operating incomeTEVA Operating marginTEVA Operating cash flowTEVA Free cash flowTEVA Capital expendituresTEVA Return on equityTEVA Stock buybacksTEVA Dividends paidTEVA Total assetsTEVA Total liabilitiesTEVA Shareholders’ equityTEVA overview →